A Study of LY2624587 in Patients With Advanced Cancer
NCT01139788
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
56
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Cancer
Interventions
DRUG:
LY2624587
Sponsor
Eli Lilly and Company